16 results on '"Pison, C."'
Search Results
2. Analysis of Spontaneous Breathing Can Predict Abnormal Lung Function in Asthma
- Author
-
Beaufils, F., primary, Girodet, P.-O., additional, Pison, C., additional, Hanusse, P., additional, Joie, J., additional, Similowski, T., additional, Laveneziana, P., additional, Marthan, R., additional, and Berger, P., additional
- Published
- 2021
- Full Text
- View/download PDF
3. BPA and Riociguat for the Management of Inoperable CTEPH: Results of the Extension Study Following the RACE Randomized Controlled Trial (RCT)
- Author
-
Jais, X., primary, Brenot, P., additional, Bouvaist, H., additional, Canuet, M., additional, Chabanne, C., additional, Chaouat, A., additional, Cottin, V., additional, Degroote, P., additional, Favrolt, N., additional, Horeau-Langlard, D., additional, Jevnikar, M., additional, Magro, P., additional, Montani, D., additional, Parent, F., additional, Pison, C., additional, Prévot, G., additional, Renard, S., additional, Savale, L., additional, Sitbon, O., additional, Trésorier, R., additional, Tromeur, C., additional, Piedvache, C., additional, Fadel, E., additional, Humbert, M., additional, and Simonneau, G., additional
- Published
- 2021
- Full Text
- View/download PDF
4. Long-Term Follow-up of Severe Emphysema Patients Treated with Zephyr Valves in the Multicenter, Randomized TRANSFORM Study
- Author
-
Slebos, D.-J., primary, Kornaszewska, M., additional, Kemp, S., additional, Kirk, A., additional, Carron, K., additional, mal, H., additional, Pison, C., additional, Downer, N., additional, Darwiche, K., additional, Rao, J., additional, Hubner, R.-H., additional, Trosini-Desert, V., additional, Eberhardt, R., additional, Derom, E., additional, Marquette, C.-H., additional, Shargill, N.S., additional, and Shah, P.L., additional
- Published
- 2021
- Full Text
- View/download PDF
5. Safety of Denervation Following Targeted Lung Denervation (TLD) Therapy for COPD: Airflow-1 Three Year Outcomes
- Author
-
Pison, C., primary, Shah, P.L., additional, Slebos, D.-J., additional, Ninane, V., additional, Janssens, W., additional, Perez, T., additional, Kessler, R., additional, Deslee, G., additional, Garner, J., additional, Abele, C., additional, Hartman, J.E., additional, and Valipour, A., additional
- Published
- 2020
- Full Text
- View/download PDF
6. A Double-Blind, Randomized, Sham-Controlled Study of Targeted Lung Denervation in Patients with Moderate to Severe COPD: Airflow-2 Two Year Outcomes
- Author
-
Valipour, A., primary, Shah, P.L., additional, Herth, F.J., additional, Pison, C., additional, Schumann, C., additional, Hubner, R.-H., additional, Bonta, P.I., additional, Kessler, R., additional, Gesierich, W., additional, Darwiche, K., additional, Lamprecht, B., additional, Perez, T., additional, Skowasch, D., additional, Deslee, G., additional, Marceau, A., additional, Sciurba, F.C., additional, Gosens, R., additional, Hartman, J.E., additional, Sirkanthan, K., additional, Duller, M., additional, and Slebos, D.-J., additional
- Published
- 2020
- Full Text
- View/download PDF
7. Body Mass Index and Exhaled Nitric Oxide in the French EGEA Study.
- Author
-
Varraso, R, primary, Bechet, M, additional, Joly, K, additional, Le Moual, N, additional, Scheinmann, P, additional, Bousquet, J, additional, Pin, I, additional, Pison, C, additional, Kauffmann, F, additional, and Nadif, R, additional
- Published
- 2009
- Full Text
- View/download PDF
8. Smoking Initiation in Asthmatics and Impact of Smoking on Asthma Incidence in the EGEA Cohort.
- Author
-
Siroux, V, primary, Vignoud, L, additional, Boudier, A, additional, Nguile Makao, M, additional, Massala Mouele, JN, additional, Le Moual, N, additional, Nadif, R, additional, Pison, C, additional, Kauffmann, F, additional, and Pin, I, additional
- Published
- 2009
- Full Text
- View/download PDF
9. Pulmonary arterial hypertension in France: results from a national registry.
- Author
-
Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier JF, Chabot F, Dromer C, Pison C, Reynaud-Gaubert M, Haloun A, Laurent M, Hachulla E, and Simonneau G
- Abstract
Rationale: Pulmonary arterial hypertension (PAH) is an orphan disease for which the trend is for management in designated centers with multidisciplinary teams working in a shared-care approach.Objective: To describe clinical and hemodynamic parameters and to provide estimates for the prevalence of patients diagnosed for PAH according to a standardized definition.Methods: The registry was initiated in 17 university hospitals following at least five newly diagnosed patients per year. All consecutive adult ( 18 yr) patients seen between October 2002 and October 2003 were to be included.Main Results: A total of 674 patients (mean +/- SD age, 50 +/- 15 yr; range, 18-85 yr) were entered in the registry. Idiopathic, familial, anorexigen, connective tissue diseases, congenital heart diseases, portal hypertension, and HIV-associated PAH accounted for 39.2, 3.9, 9.5, 15.3, 11.3, 10.4, and 6.2% of the population, respectively. At diagnosis, 75% of patients were in New York Heart Association functional class III or IV. Six-minute walk test was 329 +/- 109 m. Mean pulmonary artery pressure, cardiac index, and pulmonary vascular resistance index were 55 +/- 15 mm Hg, 2.5 +/- 0.8 L/min/m[2], and 20.5 +/- 10.2 mm Hg/L/min/m[2], respectively. The low estimates of prevalence and incidence of PAH in France were 15.0 cases/million of adult inhabitants and 2.4 cases/million of adult inhabitants/yr. One-year survival was 88% in the incident cohort.Conclusions: This contemporary registry highlights current practice and shows that PAH is detected late in the course of the disease, with a majority of patients displaying severe functional and hemodynamic compromise. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
10. Graft ischemic time and outcome of lung transplantation: a multicenter analysis.
- Author
-
Thabut G, Mal H, Cerrina J, Dartevelle P, Dromer C, Velly J, Stern M, Loirat P, Lesèche G, Bertocchi M, Mornex J, Haloun A, Despins P, Pison C, Blin D, and Reynaud-Gaubert M
- Abstract
Rationale: The effect of graft ischemic time on early graft function and long-term survival of patients who underwent lung transplantation remains controversial. Consequently, graft ischemic time has not been incorporated in the decision-making process at the time of graft acceptance. Objectives: To investigate the relationship between graft ischemic time and (1) early graft function and (2) long-term survival after lung transplantation. Measurements and main results: The data from 752 patients who underwent single lung transplantation (n = 258), bilateral lung transplantation (n = 247), and heart-lung transplantation (n = 247) in seven French transplantation centers during a 12-year period were reviewed. Independent data quality control was done to ensure the quality of the collected variables. Mean graft ischemic time was 245.8 +/- 96.4 minutes (range 50-660). After adjustment on 11 potential confounders, graft ischemic time was associated with the recipient PaO[2]/FIO[2] ratio recorded within the first 6 hours and with long-term survival in patients undergoing single or double lung transplantation but not in patients undergoing heart-lung transplantation. The relationship between graft ischemic time and survival appears to be of cubic form with a cutoff value of 330 minutes. These results were unaffected by the preservation fluid employed. Conclusions: The results of this large cohort of patients suggest a close relationship between graft ischemic time and both early gas exchange and long-term survival after single and double lung transplantation. Such relationship was not found in patients undergoing heart-lung transplantation. The expected graft ischemic time should be incorporated in the decision-making process at the time of graft acceptance. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
11. Safety and Adverse Events after Targeted Lung Denervation for Symptomatic Moderate to Severe Chronic Obstructive Pulmonary Disease (AIRFLOW). A Multicenter Randomized Controlled Clinical Trial.
- Author
-
Slebos DJ, Shah PL, Herth FJF, Pison C, Schumann C, Hübner RH, Bonta PI, Kessler R, Gesierich W, Darwiche K, Lamprecht B, Perez T, Skowasch D, Deslee G, Marceau A, Sciurba FC, Gosens R, Hartman JE, Srikanthan K, Duller M, and Valipour A
- Subjects
- Aged, Bronchodilator Agents therapeutic use, Double-Blind Method, Female, Forced Expiratory Volume, Humans, Male, Middle Aged, Pulmonary Disease, Chronic Obstructive complications, Pulmonary Disease, Chronic Obstructive physiopathology, Treatment Outcome, Bronchoscopy, Denervation, Pulmonary Disease, Chronic Obstructive surgery, Radiofrequency Ablation
- Abstract
Rationale: Targeted lung denervation (TLD) is a bronchoscopic radiofrequency ablation therapy for chronic obstructive pulmonary disease (COPD), which durably disrupts parasympathetic pulmonary nerves to decrease airway resistance and mucus hypersecretion. Objectives: To determine the safety and impact of TLD on respiratory adverse events. Methods: We conducted a multicenter, randomized, sham bronchoscopy-controlled, double-blind trial in patients with symptomatic (modified Medical Research Council dyspnea scale score, ≥2; or COPD Assessment Test score, ≥10) COPD (FEV
1 , 30-60% predicted). The primary endpoint was the rate of respiratory adverse events between 3 and 6.5 months after randomization (defined as COPD exacerbation, tachypnea, wheezing, worsening bronchitis, worsening dyspnea, influenza, pneumonia, other respiratory infections, respiratory failure, or airway effects requiring therapeutic intervention). Blinding was maintained through 12.5 months. Measurements and Main Results: Eighty-two patients (50% female; mean ± SD: age, 63.7 ± 6.8 yr; FEV1 , 41.6 ± 7.3% predicted; modified Medical Research Council dyspnea scale score, 2.2 ± 0.7; COPD Assessment Test score, 18.4 ± 6.1) were randomized 1:1. During the predefined 3- to 6.5-month window, patients in the TLD group experienced significantly fewer respiratory adverse events than those in the sham group (32% vs. 71%, P = 0.008; odds ratio, 0.19; 95% confidence interval, 0.0750-0.4923, P = 0.0006). Between 0 and 12.5 months, these findings were not different (83% vs. 90%; P = 0.52). The risk of COPD exacerbation requiring hospitalization in the 0- to 12.5-month window was significantly lower in the TLD group than in the sham group (hazard ratio, 0.35; 95% confidence interval, 0.13-0.99; P = 0.039). There was no statistical difference in the time to first moderate or severe COPD exacerbation, patient-reported symptoms, or other physiologic measures over the 12.5 months of follow-up. Conclusions: Patients with symptomatic COPD treated with TLD combined with optimal pharmacotherapy had fewer study-defined respiratory adverse events, including hospitalizations for COPD exacerbation.Clinical trial registered with www.clinicaltrials.gov (NCT02058459).- Published
- 2019
- Full Text
- View/download PDF
12. A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (TRANSFORM).
- Author
-
Kemp SV, Slebos DJ, Kirk A, Kornaszewska M, Carron K, Ek L, Broman G, Hillerdal G, Mal H, Pison C, Briault A, Downer N, Darwiche K, Rao J, Hübner RH, Ruwwe-Glosenkamp C, Trosini-Desert V, Eberhardt R, Herth FJ, Derom E, Malfait T, Shah PL, Garner JL, Ten Hacken NH, Fallouh H, Leroy S, and Marquette CH
- Subjects
- Exercise Tolerance physiology, Female, Forced Expiratory Volume physiology, Humans, Male, Middle Aged, Prospective Studies, Pulmonary Emphysema physiopathology, Quality of Life, Surveys and Questionnaires, Treatment Outcome, Prostheses and Implants, Pulmonary Emphysema therapy
- Abstract
Rationale: Single-center randomized controlled trials of the Zephyr endobronchial valve (EBV) treatment have demonstrated benefit in severe heterogeneous emphysema. This is the first multicenter study evaluating this treatment approach., Objectives: To evaluate the efficacy and safety of Zephyr EBVs in patients with heterogeneous emphysema and absence of collateral ventilation., Methods: This was a prospective, multicenter 2:1 randomized controlled trial of EBVs plus standard of care or standard of care alone (SoC). Primary outcome at 3 months post-procedure was the percentage of subjects with FEV
1 improvement from baseline of 12% or greater. Changes in FEV1 , residual volume, 6-minute-walk distance, St. George's Respiratory Questionnaire score, and modified Medical Research Council score were assessed at 3 and 6 months, and target lobe volume reduction on chest computed tomography at 3 months., Measurements and Main Results: Ninety seven subjects were randomized to EBV (n = 65) or SoC (n = 32). At 3 months, 55.4% of EBV and 6.5% of SoC subjects had an FEV1 improvement of 12% or more (P < 0.001). Improvements were maintained at 6 months: EBV 56.3% versus SoC 3.2% (P < 0.001), with a mean ± SD change in FEV1 at 6 months of 20.7 ± 29.6% and -8.6 ± 13.0%, respectively. A total of 89.8% of EBV subjects had target lobe volume reduction greater than or equal to 350 ml, mean 1.09 ± 0.62 L (P < 0.001). Between-group differences for changes at 6 months were statistically and clinically significant: ΔEBV-SoC for residual volume, -700 ml; 6-minute-walk distance, +78.7 m; St. George's Respiratory Questionnaire score, -6.5 points; modified Medical Research Council dyspnea score, -0.6 points; and BODE (body mass index, airflow obstruction, dyspnea, and exercise capacity) index, -1.8 points (all P < 0.05). Pneumothorax was the most common adverse event, occurring in 19 of 65 (29.2%) of EBV subjects., Conclusions: EBV treatment in hyperinflated patients with heterogeneous emphysema without collateral ventilation resulted in clinically meaningful benefits in lung function, dyspnea, exercise tolerance, and quality of life, with an acceptable safety profile. Clinical trial registered with www.clinicaltrials.gov (NCT02022683).- Published
- 2017
- Full Text
- View/download PDF
13. Airway Microbiota Determines Innate Cell Inflammatory or Tissue Remodeling Profiles in Lung Transplantation.
- Author
-
Bernasconi E, Pattaroni C, Koutsokera A, Pison C, Kessler R, Benden C, Soccal PM, Magnan A, Aubert JD, Marsland BJ, and Nicod LP
- Subjects
- Adult, Bronchoalveolar Lavage Fluid microbiology, Female, Graft Survival physiology, Humans, Inflammation microbiology, Male, Middle Aged, Airway Remodeling physiology, Inflammation physiopathology, Lung Transplantation, Microbiota physiology, Respiratory System microbiology
- Abstract
Rationale: In lung transplant recipients, long-term graft survival relies on the control of inflammation and tissue remodeling to maintain graft functionality and avoid chronic lung allograft dysfunction. Although advances in clinical practice have improved transplant success, the mechanisms by which the balance between inflammation and remodeling is maintained are largely unknown., Objectives: To assess whether host-microbe interactions in the transplanted lung determine the immunologic tone of the airways, and consequently could impact graft survival., Methods: Microbiota DNA and host total RNA were isolated from 203 bronchoalveolar lavages obtained from 112 patients post-lung transplantation. Microbiota composition was determined using 16S ribosomal RNA analysis, and expression of a set of genes involved in prototypic macrophage functions was quantified using real-time quantitative polymerase chain reaction., Measurements and Main Results: We show that the characteristics of the pulmonary microbiota aligned with distinct innate cell gene expression profiles. Although a nonpolarized activation was associated with bacterial communities consisting of a balance between proinflammatory (e.g., Staphylococcus and Pseudomonas) and low stimulatory (e.g., Prevotella and Streptococcus) bacteria, "inflammatory" and "remodeling" profiles were linked to bacterial dysbiosis. Mechanistic assays provided direct evidence that bacterial dysbiosis could lead to inflammatory or remodeling profiles in macrophages, whereas a balanced microbial community maintained homeostasis., Conclusions: The crosstalk between bacterial communities and innate immune cells potentially determines the function of the transplanted lung offering novel pathways for intervention strategies.
- Published
- 2016
- Full Text
- View/download PDF
14. Familial resemblance of asthma severity in the EGEA* study.
- Author
-
Pin I, Siroux V, Cans C, Kauffmann F, Maccario J, Pison C, and Dizier MH
- Subjects
- Administration, Inhalation, Adolescent, Adrenal Cortex Hormones administration & dosage, Adrenal Cortex Hormones therapeutic use, Adult, Analysis of Variance, Asthma drug therapy, Child, Female, Forced Expiratory Volume genetics, Genetic Predisposition to Disease genetics, Humans, Male, Middle Aged, Odds Ratio, Regression Analysis, Asthma genetics, Family Health, Severity of Illness Index
- Abstract
Familial resemblance of asthma is well known but epidemiological research focused on familial resemblance of asthma severity is scanty. We studied whether asthma and asthma severity in first-degree relatives of cases with asthma were related to asthma severity of the index case. The analysis was based upon the examination of 944 subjects (348 cases, 239 relatives with asthma, and 357 subjects without asthma) and upon the information on 3467 first- degree relatives of probands. The risks of asthma in relatives of adult and pediatric cases were significantly higher than in relatives of subjects without asthma (OR 3.4 [95% CI 2.5-4.7] and 4.5 [2.6- 8.1], respectively). Proportions of asthma in relatives were not related to the asthma severity of cases for the three severity criteria studied (clinical score, FEV(1) % predicted, and inhaled corticosteroid use). Using both regression models and intraclass correlation coefficients, there was a significant familial resemblance for the clinical severity score (ICC = 0.23 and 0.23) and for FEV(1) (ICC = 0.19 and 0.25) among families of pediatric and adult probands, respectively. In conclusion, asthma occurrence in relatives may be independent of the severity of the cases with asthma, but results suggest familial resemblance in the severity of asthma when it occurs.
- Published
- 2002
- Full Text
- View/download PDF
15. Increased lipid peroxidation in patients with pulmonary hypertension.
- Author
-
Cracowski JL, Cracowski C, Bessard G, Pepin JL, Bessard J, Schwebel C, Stanke-Labesque F, and Pison C
- Subjects
- Adolescent, Adult, Aged, Analysis of Variance, Biomarkers, Chromatography, Gas, Data Interpretation, Statistical, Dinoprost urine, Female, Free Radicals, Hemodynamics, Humans, Hypertension, Pulmonary etiology, Hypertension, Pulmonary physiopathology, Male, Mass Spectrometry, Middle Aged, Nitric Oxide administration & dosage, Walking, Hypertension, Pulmonary diagnosis, Hypertension, Pulmonary metabolism, Lipid Peroxidation, Oxidative Stress
- Abstract
Isoprostanes are chemically stable lipid peroxidation products of arachidonic acid, the quantification of which provides a novel approach to the assessment of oxidative stress in vivo. The main objective of this study was to quantify the urinary levels of isoprostaglandin F(2alpha) type III (iPF(2alpha)-III), an F(2)-isoprostane, in patients with pulmonary hypertension (PHT) in comparison with healthy controls. The secondary objective was to test whether baseline iPF(2alpha)-III levels correlate to the reversibility of pulmonary hypertension in response to inhaled NO challenge. Urinary iPF(2alpha)-III levels were measured by gas chromatography-mass spectrometry in 25 patients with PHT, 14 of whom were investigated for response to inhaled NO challenge. Urinary iPF(2alpha)-III levels in PHT patients (225 +/- 27 pmol/mmol creatinine) were 2.3 times as high as in controls (97 +/- 7 pmol/mmol creatinine, p < 0.001). The mean pulmonary arterial pressure variation and the pulmonary vascular resistance variation in response to inhaled NO were correlated to basal iPF(2alpha)-III levels. This study shows that oxidative stress is increased in patients with pulmonary hypertension. Furthermore, iPF(2alpha)-III levels inversely correlate to pulmonary vasoreactivity. These observations are consistent with the hypothesis that free radical generation is involved in PHT pathogenesis.
- Published
- 2001
- Full Text
- View/download PDF
16. Genome screen for asthma and related phenotypes in the French EGEA study.
- Author
-
Dizier MH, Besse-Schmittler C, Guilloud-Bataille M, Annesi-Maesano I, Boussaha M, Bousquet J, Charpin D, Degioanni A, Gormand F, Grimfeld A, Hochez J, Hyne G, Lockhart A, Luillier-Lacombe M, Matran R, Meunier F, Neukirch F, Pacheco Y, Parent V, Paty E, Pin I, Pison C, Scheinmann P, Thobie N, Vervloet D, Kauffmann F, Feingold J, Lathrop M, and Demenais F
- Subjects
- Adolescent, Asthma immunology, Asthma physiopathology, Bronchial Hyperreactivity, Child, Eosinophils, Female, France, Genetic Linkage, Genetic Markers, Genotype, Humans, Immunoglobulin E analysis, Leukocyte Count, Male, Microsatellite Repeats, Skin Tests, Asthma genetics, Genome, Phenotype
- Abstract
A genome-wide search was conducted in 107 nuclear families with at least two siblings with asthma, as part of the French EGEA study. A two-stage analysis strategy was applied to the 107 families divided into two independent subsets of 46 and 61 families, where all regions detected in the first set of families were tested for replication in the second set. In addition, all regions reported by published genome scans in different populations were examined in the total sample. A total of 254 markers were typed in the first set of families and 70% of them in the second set. Linkage was investigated by model-free methods for asthma and four asthma-related phenotypes: bronchial responsiveness (BR), skin test response, total immunoglobulin E (IgE) levels, and eosinophil count. The two-stage analysis led to the detection of three regions: 11p13 for IgE, 12q24 for eosinophils, and 17q12-21 for asthma and skin tests. Among the regions reported by published genome screens, seven were found in the 107 French EGEA families: three being already detected by the two-stage analysis, 11p13 (p = 0.005), 12q24 (p = 0.0008), and 17q12-21 (p = 0.001), and four additional ones, 1p31 (p = 0.005) for asthma, 11q13 (p = 0.006) for IgE, 13q31 (p = 0.001) for eosinophils, and 19q13 (p = 0.02) for BR.
- Published
- 2000
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.